DAVITA INC. (DVA): Results of Operations and Financial Condition
DAVITA INC. (DVA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Contact: Investor Relations DaVita Inc. ir@davita.com DaVita Inc. 2nd Quarter 2026 Results Denver, Colorado, August 4, 2026 — DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended June 30, 2026. “Thanks to the outstanding efforts of our teammates
How this was made
The 30-second read
Why it matters
Traders can update models using the reported Q2 financials (revenue, operating income, diluted EPS, operating cash flow, free cash flow) and the stated 2026 adjusted operating income and adjusted diluted net income per share guidance range. The incremental term loan and ongoing repurchases add a capital structure and shareholder return angle.
Market read
A same-day 8-K provides actionable quarterly datapoints and a 2026 adjusted guidance range, which can drive earnings-model revisions and near-term positioning.
What to watch
The filing does not provide GAAP operating income or GAAP cash flow guidance, and it references 2025 cybersecurity incident impacts in G&A, which may affect comparability and investor interpretation.
DaVita reported consolidated revenues of $3.554 billion, operating income of $579 million and diluted earnings per share of $4.02 for the quarter ended June 30, 2026.
Quarterly operating income, net income, diluted earnings per share, operating cash flow and free cash flow were higher than the prior quarter or prior-year comparison disclosed, while U.S. treatment volume increased per day from the first quarter and the company maintained 2026 guidance.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Consolidated revenuesGAAP | $3.554 billion | – | – |
| Net income attributable to DaVita Inc.GAAP | $265 million | – | – |
| Diluted earnings per shareGAAP | $4.02 | – | – |
| Adjusted net incomenon-GAAP | $265 million | – | – |
| Adjusted diluted earnings per sharenon-GAAP | $4.02 | – | – |
| Operating incomeGAAP | $579 million | – | – |
| Operating income marginGAAP | 16.3 % | – | – |
| Adjusted operating incomenon-GAAP | $579 million | – | – |
| Adjusted operating income marginnon-GAAP | 16.3 % | – | – |
| Six months ended June 30 net income attributable to DaVita Inc.GAAP | $463 million | – | – |
| Six months ended June 30 diluted earnings per shareGAAP | $6.86 | – | – |
| Six months ended June 30 adjusted net incomenon-GAAP | $463 million | – | – |
| Six months ended June 30 adjusted diluted earnings per sharenon-GAAP | $6.86 | – | – |
| Six months ended June 30 operating incomeGAAP | $1,061 million | – | – |
| Six months ended June 30 operating income marginGAAP | 15.2 % | – | – |
| Six months ended June 30 adjusted operating incomenon-GAAP | $1,061 million | – | – |
| Six months ended June 30 adjusted operating income marginnon-GAAP | 15.2 % | – | – |
| Operating cash flowGAAP | $490 million | – | – |
| Free cash flownon-GAAP | $256 million | – | – |
| Twelve months ended June 30 operating cash flowGAAP | $2,193 million | – | – |
| Twelve months ended June 30 free cash flownon-GAAP | $1,308 million | – | – |
| Total U.S. dialysis treatmentsother | 7,226,600 | – | – |
| Average U.S. dialysis treatments per dayother | 92,649 treatments per day | 1.09% | – |
| Normalized non-acquired treatment growthother | 0.3% | – | 0.3% |
| Revenue per treatmentother | $415.87 | $(1.72) | – |
| Patient care costs per treatmentother | $277.40 | $(2.71) | – |
| General and administrativeother | $331 million | $11 million | – |
| Six months ended June 30 revenue per treatmentother | $416.71 | – | $14.33 |
| Six months ended June 30 patient care costs per treatmentother | $278.74 | – | $8.69 |
| Six months ended June 30 general and administrativeother | $651 million | – | $56 million |
| Effective income tax rate on incomeGAAP | 21.1 % | – | – |
| Effective income tax rate on income attributable to DaVita Inc.non-GAAP | 25.6 % | – | – |
| Six months ended June 30 effective income tax rate on incomeGAAP | 20.4 % | – | – |
| Six months ended June 30 effective income tax rate on income attributable to DaVita Inc.non-GAAP | 25.4 % | – | – |
Current 2026 guidance outlook
- NoteAdjusted operating income $2,150 million to $2,250 million
- NoteAdjusted diluted net income per share attributable to DaVita Inc. $14.10 to $15.20
- NoteFree cash flow $1,000 million to $1,250 million
Capital returns
- During the three months ended June 30, 2026, repurchased 2.2 million shares for $348 million, at an average price paid of $154.95 per share.
- Subsequent to June 30, 2026 through August 4, 2026, repurchased 0.2 million shares of common stock for $37 million at an average price paid of $199.55 per share.
What drove it
- The per-day increase in U.S. dialysis treatments versus the first quarter was 1.09%.
- The quarter change in revenue per treatment was primarily driven by changes in payor mix and other normal fluctuations, partially offset by the seasonal impact of co-insurance and deductibles and an increase in average rates.
- The quarter change in patient care costs per treatment was primarily due to decreases in payroll taxes and pharmaceutical costs, partially offset by increased health benefits expenses.
- Fixed direct operating expenses favorably impacted patient care costs per treatment due to increased treatments in the second quarter.
- The quarter change in general and administrative expense was primarily due to increased professional fees.
Concerns
- Normalized non-acquired treatment growth in the second quarter of 2026 compared to the second quarter of 2025 was 0.3%.
- Revenue per treatment declined by $(1.72) from the first quarter of 2026.
- Increased health benefits expenses partially offset declines in payroll taxes and pharmaceutical costs.
- The release identifies risks relating to government funding and reimbursement rates, patient and payor mix, supply availability and costs, trade policies and tariffs, labor-market conditions, competition, and innovative technologies, drugs or other treatments.
What to watch
- Normalized non-acquired treatment growth and treatment volume.
- Payor mix, average rates, and the seasonal impact of co-insurance and deductibles on revenue per treatment.
- Compensation, insurance, health benefits, IT-related costs, professional fees, and pharmaceutical costs.
- Delivery against Current 2026 guidance for adjusted operating income, adjusted diluted net income per share attributable to DaVita Inc., and free cash flow.
- Use of the remaining Term Loan B-2 proceeds and additional share repurchases.
Balance sheet and cash flow
- In June 2026, entered into the Ninth Amendment to the senior secured credit agreement, extending an incremental Term Loan B-2 tranche in the aggregate principal amount of $500 million.
- A portion of the net proceeds was used to repay a portion of the balance outstanding on the revolving line of credit and related accrued interest and fees.
- The remaining borrowings added cash to the balance sheet for general corporate purposes.
- Operating cash flow was $490 million and free cash flow was $256 million.
Analysis
DaVita reported consolidated revenues of $3.554 billion for the quarter ended June 30, 2026. Operating income was $579 million with a 16.3 % margin, compared with $482 million and a 14.1 % margin in the first quarter of 2026. Net income attributable to DaVita Inc. was $265 million and diluted earnings per share was $4.02, compared with $198 million and $2.87, respectively, in the first quarter. Adjusted operating income and adjusted net income were each the same as their reported counterparts for the quarter.
U.S. dialysis activity increased sequentially. Total U.S. dialysis treatments were 7,226,600, averaging 92,649 treatments per day, with a per-day increase of 1.09% compared with the first quarter. Normalized non-acquired treatment growth was 0.3% compared with the second quarter of 2025. Revenue per treatment was $415.87, down $(1.72) from the first quarter, as changes in payor mix and other normal fluctuations were partially offset by the seasonal impact of co-insurance and deductibles and an increase in average rates.
Cost trends supported the quarterly operating result. Patient care costs per treatment declined $(2.71) to $277.40, driven primarily by decreases in payroll taxes and pharmaceutical costs, partly offset by increased health benefits expenses. The company also cited increased treatments as a favorable factor for fixed direct operating expenses per treatment. General and administrative expense increased $11 million to $331 million, primarily due to increased professional fees.
Cash generation was stronger against the disclosed prior-year comparison. Operating cash flow was $490 million compared with $324 million, while free cash flow was $256 million compared with $157 million. Over the twelve months ended June 30, 2026, operating cash flow was $2,193 million and free cash flow was $1,308 million. Capital allocation included $348 million used to repurchase 2.2 million shares during the quarter, followed by $37 million for 0.2 million shares through August 4, 2026. The company also added a $500 million incremental Term Loan B-2 tranche, used part of the proceeds to repay revolving credit borrowings and retained remaining borrowings as cash for general corporate purposes.
DaVita maintained Current 2026 guidance of $2,150 million to $2,250 million for adjusted operating income, $14.10 to $15.20 for adjusted diluted net income per share attributable to DaVita Inc., and $1,000 million to $1,250 million for free cash flow. The principal reported operating items to monitor are treatment growth, payor mix and revenue per treatment, health-benefit and other patient-care costs, and general and administrative spending.
Management, verbatim
Thanks to the outstanding efforts of our teammates, we had another positive quarter for both patient outcomes and financial results.
Javier Rodriguez, CEO of DaVita Inc.
As we look to the rest of the year, we maintain our strategic focus on exciting new innovations in kidney dialysis to enhance the lives of our patients.
Javier Rodriguez, CEO of DaVita Inc.
Not in the filing
stated, not guessed- Prior-year and prior-quarter consolidated revenue
- Consolidated revenue year-over-year and quarter-over-quarter change
- Gross profit and gross margin
- GAAP net income margin and adjusted net income margin
- Second-quarter prior-year net income, diluted earnings per share, adjusted net income, adjusted diluted earnings per share, operating income, and adjusted operating income
- Second-quarter year-over-year changes for earnings and operating income metrics
- Cash balance
- Total debt balance
- Capital expenditures
- Dividend information
- Segment revenue disclosure
- Revenue, gross margin, operating expense, and tax-rate guidance
- Prior outlook for comparison with actual results
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
DaVita filed an SEC Form 8-K with its Q2 2026 results for the quarter ended June 30, 2026, including operating metrics, cash flow, capital allocation, and 2026 adjusted guidance.
Ticker impact
DaVita reported Q2 2026 results and disclosed $500M incremental Term Loan B-2, $348M buybacks, and 2026 adjusted guidance range.
Likely supportive for near-term sentiment if guidance range and cash flow/free cash flow remain credible; debt-funded buyback may be viewed as capital-return supportive but leverage-sensitive.
The filing includes concrete Q2 revenue, operating income, EPS, operating cash flow/free cash flow, and a 2026 adjusted guidance range, which are direct inputs to valuation and positioning. The incremental term loan and buyback provide additional capital allocation signals that can move the stock, though the article does not provide GAAP operating income/cash flow guidance.
Market effects
Dialysis operators may see read-across from DaVita’s treatment volume, revenue per treatment, and cost trends, especially around payor mix and patient care cost per treatment.
Primarily US healthcare services sentiment given the focus on US dialysis metrics and Medicare base rate drivers.
Limited, as the disclosure is mostly US-centric with only high-level international center counts and integrated care spend.
Counterpoint
Capital return via buybacks funded partly by incremental debt could raise leverage concerns if reimbursement or cost trends deteriorate.
Key entities
- public_companyDaVita Inc.
Subject of the filing, reporting Q2 2026 results and providing 2026 adjusted guidance plus debt and buyback details.
- debt_instrumentTerm Loan B-2 (Ninth Amendment)
Incremental $500M tranche extended via amendment, with proceeds used partly to repay revolver and for general corporate purposes.
- capital_returnShare repurchases
Repurchased 2.2M shares in Q2 at an average $154.95, with additional repurchases after quarter-end.
